Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Non-Current Liabilities (2016 - 2022)

Cardiff Oncology (CRDF) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $9.8 million as the latest value for Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 7.9% to $9.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Dec 2022, up 7.9% year-over-year, with the annual reading at $9.8 million for FY2022, 7.9% up from the prior year.
  • Total Non-Current Liabilities hit $9.8 million in Q4 2022 for Cardiff Oncology, up from $9.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $9.8 million in Q4 2022 to a low of $3.9 million in Q3 2018.
  • Historically, Total Non-Current Liabilities has averaged $5.7 million across 5 years, with a median of $5.3 million in 2019.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 78.44% in 2018 and later skyrocketed 45.24% in 2021.
  • Year by year, Total Non-Current Liabilities stood at $4.1 million in 2018, then skyrocketed by 42.29% to $5.8 million in 2019, then increased by 8.89% to $6.3 million in 2020, then surged by 45.24% to $9.1 million in 2021, then grew by 7.9% to $9.8 million in 2022.
  • Business Quant data shows Total Non-Current Liabilities for CRDF at $9.8 million in Q4 2022, $9.1 million in Q4 2021, and $7.8 million in Q3 2021.